Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Cash from Investing Activities: 2013-2024

Historic Cash from Investing Activities for Astria Therapeutics (ATXS) over the last 12 years, with Dec 2024 value amounting to -$191.9 million.

  • Astria Therapeutics' Cash from Investing Activities fell 420.29% to -$3.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.1 million, marking a year-over-year increase of 41.93%. This contributed to the annual value of -$191.9 million for FY2024, which is 242.07% down from last year.
  • Per Astria Therapeutics' latest filing, its Cash from Investing Activities stood at -$191.9 million for FY2024, which was down 242.07% from $135.1 million recorded in FY2023.
  • Over the past 5 years, Astria Therapeutics' Cash from Investing Activities peaked at $135.1 million during FY2023, and registered a low of -$191.9 million during FY2024.
  • For the 3-year period, Astria Therapeutics' Cash from Investing Activities averaged around -$74.6 million, with its median value being -$167.1 million (2022).
  • As far as peak fluctuations go, Astria Therapeutics' Cash from Investing Activities soared by 254.34% in 2020, and later tumbled by 1,231.17% in 2022.
  • Over the past 5 years, Astria Therapeutics' Cash from Investing Activities (Yearly) stood at $6.3 million in 2020, then crashed by 299.29% to -$12.6 million in 2021, then plummeted by 1,231.17% to -$167.1 million in 2022, then spiked by 180.81% to $135.1 million in 2023, then slumped by 242.07% to -$191.9 million in 2024.